Tozaki H, Odoriba T, Iseki T, Taniguchi T, Fujita T, Murakami M, Muranishi S, Yamamoto A
Kyoto Pharmaceutical University, Department of Biopharmaceutics, Japan.
J Pharm Pharmacol. 1998 Aug;50(8):913-20. doi: 10.1111/j.2042-7158.1998.tb04008.x.
The objective of this study was to examine the effects of protease inhibitors on the absorption of calcitonin from different regions of the intestine in rats. The absorption experiments were investigated by in-situ use of closed intestinal loops in rats and stability of calcitonin was examined in mucosal homogenates and intestinal fluids. The intestinal absorption of calcitonin was evaluated by measurement of its hypocalcaemic effect. No substantial hypocalcaemic response was observed when calcitonin was administered into the jejunum or colon. A slight hypocalcaemic effect was observed after administration of calcitonin into the ileum. Of the co-administered protease inhibitors, bacitracin (20mM) strongly promoted calcitonin absorption from the jejunum, ileum and colon. A significant hypocalcaemic effect was also obtained after intestinal administration of calcitonin with soybean trypsin inhibitor (10mgmL(-1)), camostat mesylate (20mM) or aprotinin (2mgmL(-1)). In the stability experiment, bacitracin reduced the degradation of calcitonin in the different intestinal homogenates. Soybean trypsin inhibitor significantly reduced the degradation of calcitonin in the fluids of the small intestine. We also examined the different endopeptidases in gut luminal fluids and the different exopeptidases in gut mucosal homogenates of rats. The ranking order for the total endopeptidase activity of the intestinal fluids was jejunum > ileum > colon. That for total exopeptidase activity of the intestinal mucosa was jejunum > ileum > colon. These results suggest that endo- and exopeptidases might be responsible for the hydrolysis of calcitonin and that protease inhibitors might usefully improve absorption of calcitonin to the systemic circulation from the large intestine.
本研究的目的是考察蛋白酶抑制剂对大鼠肠道不同部位降钙素吸收的影响。通过在大鼠体内原位使用封闭肠袢进行吸收实验,并在黏膜匀浆和肠液中检测降钙素的稳定性。通过测量降钙素的降血钙作用来评估其肠道吸收情况。将降钙素注入空肠或结肠时未观察到明显的降血钙反应。将降钙素注入回肠后观察到轻微的降血钙作用。在共同给予的蛋白酶抑制剂中,杆菌肽(20mM)强烈促进降钙素从空肠、回肠和结肠的吸收。将降钙素与大豆胰蛋白酶抑制剂(10mgmL(-1))、甲磺酸卡莫司他(20mM)或抑肽酶(2mgmL(-1))经肠道给药后也获得了显著的降血钙作用。在稳定性实验中,杆菌肽减少了降钙素在不同肠匀浆中的降解。大豆胰蛋白酶抑制剂显著减少了降钙素在小肠液中的降解。我们还检测了大鼠肠腔液中的不同内肽酶和肠黏膜匀浆中的不同外肽酶。肠液中总内肽酶活性的排序为空肠>回肠>结肠。肠黏膜中总外肽酶活性的排序为空肠>回肠>结肠。这些结果表明,内肽酶和外肽酶可能是导致降钙素水解的原因,蛋白酶抑制剂可能有助于改善降钙素从大肠到体循环的吸收。